Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rollover Platform Study for Continued Study Treatment and Ongoing Safety Monitoring
NCT06788509Phase 1Enrolling by invitation
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2024
- Primary completion
- Jan 2028
- Modality
- IgG Antibodies, Antibody Conjugates, Small Molecules
- Countries
- 15
01
Overview
Phase 1, open-label, single-arm trial of rezetamig, JNJ-67856633, ibrutinib, JNJ-64264681, JNJ-74856665 and 4 more in acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), myelodysplastic syndrome (MDS) and 3 more, sponsored by Janssen Pharmaceutical. Primary endpoint: Number of Participants with Serious Adverse Events (SAEs) and Grade Greater than or equals to (>=) 3 Related Adverse Events (AEs). Started Dec 2024; status: enrolling by invitation.
02
Drugs
rezetamigJNJ-67856633ibrutinibJNJ-64264681JNJ-74856665
03
Conditions
acute myeloid leukemia (AML)non-Hodgkin lymphoma (NHL)myelodysplastic syndrome (MDS)chronic lymphocytic leukemia (CLL)solid tumor
Beyond the preview
Go deeper on NCT06788509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06788509.